AstraZeneca's Ultomiris Lowers Proteinuria Levels in Late-stage Kidney Disease Trial
Idag, 08:31
02:31 AM EDT, 04/21/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Tuesday that its immunoglobulin A nephropathy treatment Ultomiris showed a significant reduction of proteinuria in patients at risk of disease progression during a late-stage trial.
According to a prespecified interim analysis of the phase 3 I Can trial, Ultomiris showed a rapid reduction in proteinuria as early as week 10 of treatment. The study involved 510 participants from 28 countries.
The drugmaker said it plans to seek accelerated approval for Ultomiris in key markets.
IgAN is a rare, inflammatory kidney disease that can lead to chronic kidney disease and progress to end-stage kidney disease.
Ämnen i artikeln
AstraZeneca's Ultomiris Lowers Proteinuria Levels in Late-stage Kidney Disease Trial
Idag, 08:31
02:31 AM EDT, 04/21/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) said Tuesday that its immunoglobulin A nephropathy treatment Ultomiris showed a significant reduction of proteinuria in patients at risk of disease progression during a late-stage trial.
According to a prespecified interim analysis of the phase 3 I Can trial, Ultomiris showed a rapid reduction in proteinuria as early as week 10 of treatment. The study involved 510 participants from 28 countries.
The drugmaker said it plans to seek accelerated approval for Ultomiris in key markets.
IgAN is a rare, inflammatory kidney disease that can lead to chronic kidney disease and progress to end-stage kidney disease.
Ämnen i artikeln
Rapporter
Banker
Analys
Rapporter
Banker
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
